X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
male (10) 10
middle aged (10) 10
female (9) 9
aged (8) 8
hematology (8) 8
index medicus (7) 7
multiple myeloma - drug therapy (7) 7
bortezomib (6) 6
oncology (6) 6
stem-cell transplantation (6) 6
disease-free survival (5) 5
multiple myeloma (5) 5
multiple myeloma - mortality (5) 5
therapy (5) 5
adult (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
chemotherapy (4) 4
dexamethasone (4) 4
melphalan - administration & dosage (4) 4
salvage therapy (4) 4
survival (4) 4
thalidomide - administration & dosage (4) 4
treatment outcome (4) 4
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
boronic acids - administration & dosage (3) 3
induction (3) 3
melphalan (3) 3
multiple-myeloma (3) 3
prednisone (3) 3
prednisone - administration & dosage (3) 3
pyrazines - administration & dosage (3) 3
thalidomide (3) 3
transplantation, autologous (3) 3
abridged index medicus (2) 2
aged patients (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic agents, alkylating - administration & dosage (2) 2
autologous transplantation (2) 2
boronic acids - adverse effects (2) 2
cancer research (2) 2
clinical trials (2) 2
combined modality therapy (2) 2
complete response (2) 2
criteria (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
doxorubicin (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
elderly-patients (2) 2
incidence (2) 2
kaplan-meier estimate (2) 2
lenalidomide (2) 2
medicine, general & internal (2) 2
melphalan - adverse effects (2) 2
minimal residual disease (2) 2
multiple myeloma - genetics (2) 2
multiple myeloma - pathology (2) 2
multiple myeloma - therapy (2) 2
prednisone - adverse effects (2) 2
prognosis (2) 2
prospective studies (2) 2
pyrazines - adverse effects (2) 2
stem cell transplantation (2) 2
thalidomide - adverse effects (2) 2
thalidomide - therapeutic use (2) 2
transplantation (2) 2
trial (2) 2
vincristine (2) 2
acute promyelocytic leukaemia (1) 1
adjuvants, immunologic - therapeutic use (1) 1
administration, oral (1) 1
adolescent (1) 1
algorithms (1) 1
alternating combination chemotherapy (1) 1
antigens, cd34 - metabolism (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents, alkylating - adverse effects (1) 1
antineoplastic agents, hormonal - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
bone marrow transplantation - immunology (1) 1
bone marrow transplantation - methods (1) 1
bone-marrow (1) 1
bortezomib - therapeutic use (1) 1
bortezomib-melphalan-prednisone (1) 1
cancer (1) 1
cardiology (1) 1
care and treatment (1) 1
chemotherapy, adjuvant (1) 1
chi-square distribution (1) 1
colony-stimulating factor (1) 1
combination (1) 1
comparative analysis (1) 1
cyclophosphamide (1) 1
cyclophosphamide - adverse effects (1) 1
daratumumab (1) 1
data processing (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2077 - 2084
Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 367, Issue 9513, pp. 825 - 831
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 7, pp. 2767 - 2772
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5636 - 5636
Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory... 
Journal Article
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 10, pp. 1873 - 1879
Abstract High-dose (200 mg/m2, MEL200) and intermediate-dose melphalan (100 mg/m2, MEL100) showed significant activity in myeloma. In a phase 3 study, 298... 
Journal Article
JOURNAL OF CLINICAL MEDICINE, ISSN 2077-0383, 06/2019, Volume 8, Issue 6, p. 877
Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory... 
DIAGNOSED MULTIPLE-MYELOMA | SURVIVAL | DARATUMUMAB | CRITERIA | multiple myeloma | MULTICENTER | BORTEZOMIB | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | PREDNISONE | THERAPY | KRd regimen | salvage therapy | MELPHALAN
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 196 - 196
Abstract Background: The phase 3 GIMEMA-MMY-3006 study comparing bortezomib-thalidomide-dexamethasone (VTD) vs. thalidomide-dexamethasone (TD) as induction... 
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2005, Volume 104, Issue 7, pp. 1428 - 1433
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2077 - 2077
Abstract Background and aims The extensive use of new drugs in multiple myeloma (MM) allowed the achievement of unprecedented levels of cytoreduction and major... 
Journal Article
Leukemia Research, ISSN 0145-2126, 2010, Volume 35, Issue 7, pp. 899 - 903
Journal Article
by Mohty, Mohamad and Terpos, Evangelos and Mateos, Maria-Victoria and Cavo, Michele and Lejniece, Sandra and Beksac, Meral and Bekadja, Mohamed Amine and Legiec, Wojciech and Dimopoulos, Meletios and Stankovic, Svetlana and Durán, Maria Soledad and De Stefano, Valerio and Corso, Alessandro and Kochkareva, Yulia and Laane, Edward and Berthou, Christian and Salwender, Hans and Masliak, Zvenyslava and Pečeliūnas, Valdas and Willenbacher, Wolfgang and Silva, João and Louw, Vernon and Nemet, Damir and Borbényi, Zita and Abadi, Uri and Pedersen, Robert Schou and Černelč, Peter and Potamianou, Anna and Couturier, Catherine and Feys, Caroline and Thoret-Bauchet, Florence and Boccadoro, Mario and Bekadja, Mohamed and Hamladji, Rose-Marie and Ali, Hocine Ait and Hamdi, Selma and Touhami, Hadj and Mansour, Nourredine Sidi and Linkesch, Werner and Abildgaard, Niels and Hein, Marju and Eveillard, Jean Richard and Yamani, Abderrazak el and Moreau, Philippe and Sanhes, Laurence and Lepeu, Gérard and Laribi, Kamel and Jourdan, Eric and Fitoussi, Olivier and Allangba, Olivier and Fleury, Joël and Escoffre, Martine and Benramdane, Riad and Cartron, Guillaume and Dine, Gérard and Legouffe, Eric and Harich, Hanns-Detlev and Illmer, Thomas and Dörfel, Steffen and Hannig, Carla Verena and Koenigsmann, Michael and Prange-Krex, Gabriele and Tamm, Ingo and Zeller, Wolfgang and Maasberg, Michael and Schlag, Rudolf and Klausmann, Martine and Uhlig, Jens and Alkemper, Burkhard and Schütz, Stefan and Tessen, Hans-Werner and Mohr, Benno and Schmidt, Peter and Heinrich, Bernhard and Hebart, Holger and Seipelt, Gernot and Zoeller, Thomas and Heits, Frank and Müller-Naendrup, Clemens and Hansen, Richard and Repp, Roland and Von Weikersthal, Ludwig Fischer and Schmits, Rudolf and Heßling, Jörg and Krammer-Steiner, B and Janzen, Viktor and Schauer, Michael and Grüner, Marcus W and Kisro, Jens and Denzlinger, Claudio and Freier, Werner and Junghanss, Christian and Görner, Martin and Laichinger, Katharina and Ostermann, Helmut and Dürk, Heinz and Hess, Georg and Reich, Gernot and Matsouka, Panagiota and Pouli, Anastasia and ... and EMMOS Investigators
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 10/2018, Volume 18, Issue 10, pp. e401 - e419
Multiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the... 
Stem cell transplantation | Observational study | Bortezomib | Routine practice | Global | UNITED-STATES | SURVIVAL | GUIDELINES | INDUCTION | PLUS DEXAMETHASONE | ONCOLOGY | TREATMENT PATTERNS | THERAPIES | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article